ES2061855T3 - Un metodo para la preparacion de un derivado de factor de crecimiento de fibroblastos basico humano o bovino. - Google Patents

Un metodo para la preparacion de un derivado de factor de crecimiento de fibroblastos basico humano o bovino.

Info

Publication number
ES2061855T3
ES2061855T3 ES89117112T ES89117112T ES2061855T3 ES 2061855 T3 ES2061855 T3 ES 2061855T3 ES 89117112 T ES89117112 T ES 89117112T ES 89117112 T ES89117112 T ES 89117112T ES 2061855 T3 ES2061855 T3 ES 2061855T3
Authority
ES
Spain
Prior art keywords
growth factor
derivatives
fibroblast growth
bfgf
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89117112T
Other languages
English (en)
Inventor
Laura Bergonzoni
Antonella Isacchi
Paolo Sarmientos
Gilles Cauet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Carlo Erba SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmitalia Carlo Erba SRL, Carlo Erba SpA filed Critical Farmitalia Carlo Erba SRL
Application granted granted Critical
Publication of ES2061855T3 publication Critical patent/ES2061855T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Eye Examination Apparatus (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

EL PRESENTE INVENTO SE REFIERE A LA PRODUCCION, MEDIANTE TECNICA DE DNA RECOMBINANTE, DE DERIVADOS DEL FACTOR DEL CRECIMIENTO FIBROBLASTICO BASICO (BFGF). ESTOS DERIVADOS DEL (BFGF) PUEDEN ACTUAR COMO ANTAGONISTAS Y / O SUPERANTAGONISTAS DE LA MOLECULA DE TIPO SALVAJE EN EL PROCESO ANGIOGENICO.ESTOS DERIVADOS ASI COMO EL BFGF DE TIPO SALVAJE, PUEDEN PREPARARSE MEDIANTE EL USO DE CADENAS DE "E. COLI" QUE HAYAN SIDO TRANSFORMADAS CON PLASMIDOS QUE LLEVEN UNA CODIFICACION DE SECUENCIA NUCLEOTOIDE PARA BFGF HUMANO Y BOBINO Y SUS DERIVADOS.
ES89117112T 1988-09-16 1989-09-15 Un metodo para la preparacion de un derivado de factor de crecimiento de fibroblastos basico humano o bovino. Expired - Lifetime ES2061855T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888821795A GB8821795D0 (en) 1988-09-16 1988-09-16 New derivatives of human/bovine basic fibroplast growth factor

Publications (1)

Publication Number Publication Date
ES2061855T3 true ES2061855T3 (es) 1994-12-16

Family

ID=10643728

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89117112T Expired - Lifetime ES2061855T3 (es) 1988-09-16 1989-09-15 Un metodo para la preparacion de un derivado de factor de crecimiento de fibroblastos basico humano o bovino.

Country Status (21)

Country Link
EP (2) EP0363675B1 (es)
JP (1) JP2888575B2 (es)
KR (1) KR900702027A (es)
CN (1) CN1041181A (es)
AT (1) ATE98693T1 (es)
AU (1) AU620925B2 (es)
CA (1) CA1340834C (es)
DE (1) DE68911461T2 (es)
DK (1) DK120290A (es)
ES (1) ES2061855T3 (es)
FI (1) FI902391A0 (es)
GB (1) GB8821795D0 (es)
HU (1) HUT53937A (es)
IL (1) IL91615A0 (es)
MY (1) MY104910A (es)
NO (1) NO902176L (es)
NZ (1) NZ230621A (es)
PT (1) PT91719B (es)
WO (1) WO1990002800A1 (es)
YU (1) YU179489A (es)
ZA (1) ZA897020B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143829A (en) * 1990-03-29 1992-09-01 California Biotechnology Inc. High level expression of basic fibroblast growth factor having a homogeneous n-terminus
US5478804A (en) * 1990-09-19 1995-12-26 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
US6833354B1 (en) 1990-12-19 2004-12-21 Kaken Pharmaceutical Co., Ltd. Agent for the treatment of bone diseases
JP3135138B2 (ja) * 1990-12-19 2001-02-13 科研製薬株式会社 骨疾患治療剤
DE69205466T2 (de) * 1991-03-21 1996-05-30 Procter & Gamble Mittel zur Kontrolle von Hautfalten, die die Arg-Ser-Arg-Lys-Sequenzen enthalten.
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
TW275068B (es) * 1993-09-24 1996-05-01 American Cyanamid Co
AUPO247496A0 (en) 1996-09-23 1996-10-17 Resmed Limited Assisted ventilation to match patient respiratory need
US6214795B1 (en) * 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
US6274712B1 (en) 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
FR2780416B1 (fr) * 1998-06-10 2002-12-20 Rhone Poulenc Nutrition Animal Procede industriel de production de proteines heterologues chez e. coli et souches utiles pour le procede
EP1207900A2 (en) * 1999-08-13 2002-05-29 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow
DE69933057T2 (de) * 1999-12-22 2007-03-15 Ortho-Mcneil Pharmaceutical, Inc. Analoge des humanen basischen fibroblasten-wachstumsfactors
CA2430112C (en) 2000-11-27 2010-07-27 Dnavec Research Inc. Paramyxovirus vector encoding angiogenesis gene and use thereof
WO2013090919A1 (en) * 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Fgf-2 having enhanced stability
CN106957359B (zh) * 2016-08-31 2020-04-24 黄志锋 Fgf1突变体及其医药应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81839A0 (en) * 1986-03-14 1987-10-20 Takeda Chemical Industries Ltd Polypeptide,dna and its use
AU1185488A (en) * 1987-01-16 1988-08-10 Amgen, Inc. Production of fibroblast growth factor
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
JP2879148B2 (ja) * 1987-07-07 1999-04-05 サイオス インコーポレイテッド 組換え繊維芽細胞成長因子
EP0326907A1 (en) * 1988-01-26 1989-08-09 Takeda Chemical Industries, Ltd. Polypeptide, DNA and its use

Also Published As

Publication number Publication date
DE68911461D1 (de) 1994-01-27
WO1990002800A1 (en) 1990-03-22
EP0363675A1 (en) 1990-04-18
NZ230621A (en) 1992-06-25
EP0396664A1 (en) 1990-11-14
ZA897020B (en) 1990-08-29
ATE98693T1 (de) 1994-01-15
NO902176L (no) 1990-07-13
DK120290A (da) 1990-07-16
MY104910A (en) 1994-06-30
HU895573D0 (en) 1990-11-28
YU179489A (en) 1991-10-31
FI902391A0 (fi) 1990-05-14
CA1340834C (en) 1999-11-30
IL91615A0 (en) 1990-04-29
AU4317189A (en) 1990-04-02
DE68911461T2 (de) 1994-05-19
GB8821795D0 (en) 1988-10-19
PT91719B (pt) 1995-05-31
AU620925B2 (en) 1992-02-27
EP0363675B1 (en) 1993-12-15
PT91719A (pt) 1990-03-30
DK120290D0 (da) 1990-05-15
JPH03501855A (ja) 1991-04-25
JP2888575B2 (ja) 1999-05-10
KR900702027A (ko) 1990-12-05
NO902176D0 (no) 1990-05-15
HUT53937A (en) 1990-12-28
CN1041181A (zh) 1990-04-11

Similar Documents

Publication Publication Date Title
ES2061855T3 (es) Un metodo para la preparacion de un derivado de factor de crecimiento de fibroblastos basico humano o bovino.
PT955313E (pt) Nova proteina e processo para a sua producao
GR3020517T3 (en) Human erythropoietin muteins, their production and their use
AU7180787A (en) Fibroblast growth factor
DK0458959T3 (da) Hidtil ukendte blodpladeafledte vækstfaktor B-kædeanaloger og fremgangsmåde til homogen fremstilling deraf
EP0237966A3 (en) Human basic fibroblast growth factor
ATE127844T1 (de) Dns und ihre verwendung.
HU9200548D0 (en) Improved activity process of recombined proteins
PT92603A (pt) Processo de producao de factor de crescimento transformante, quimerico,beta
DK38889D0 (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
FI890342A0 (fi) Hjaernmitogener, som binds till heparin.
FI102383B1 (fi) Menetelmä ja plasmidi modifioidun PE40-domeenia sisältävän hybridiproteiinin valmistamiseksi
EP0315118A3 (en) Dna coding for endothelin and use thereof
EP0276778A3 (en) High level expression in e. coli of soluble mature hil-1beta and derivatives with altered biological activity
EP0241136A3 (en) Human class 1 heparin-binding growth factor
DE3856392D1 (de) Klonierung von Malaria-spezifischen DNA-Sequenzen:Isolierung des Gens für das 140 kd Protein
DK0555785T3 (da) Glat-muskel-mitogent stof og DNA, der koder herfor
SE8403929D0 (sv) Recombinant dna molecule, transformed microorganisms and process for producing penicillin v amidase
Bergonzoni et al. Deletion mutant of basic fibroblast growth factor and production thereof
DE59106997D1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
EP0446361A4 (en) Polypeptide, production thereof, and pharmaceutical composition and cosmetic containing said polypeptide
FI964648A (fi) Menetelmä erytropoietiinianalogien valmistamiseksi ja niiden koodaavia DNA-sekvensseja
FI934079A (fi) Menetelmä fuusioproteiinin valmistamiseksi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 363675

Country of ref document: ES